Grazitti Interactive Named Leader in the ISG Provider Lens™ Salesforce Ecosystem Partners 2025 U.S. Quadrant Report
'Grazitti's success is driven by innovations in AI and the development of products that address specific business needs'— Rodrigo Barreto, Lead Analyst at ISG
CA, UNITED STATES, April 30, 2025 / EINPresswire.com / -- Grazitti Interactive, a global digital services provider, has been named a leader in the ISG Provider Lens™ Salesforce Ecosystem Partners 2025 U.S. Quadrant Report. This recognition underscores Grazitti's commitment to delivering exceptional Salesforce solutions and services.
The report names Grazitti as a Leader in two key categories:
Implementation Services for Core Clouds and AI Agents — Midmarket: Recognized for its robust capabilities in implementing Salesforce's core cloud solutions tailored for midmarket enterprises.
Managed Application Services — Midmarket: Commended for delivering efficient and reliable managed services that enhance the Salesforce experience for midmarket clients.
Atul Sharma, Vice President of Salesforce Practice at Grazitti Interactive, stated, 'Being recognized as a Leader reflects our unwavering dedication to excellence in Salesforce implementations and managed services. We remain committed to leveraging Salesforce's evolving capabilities to drive innovation and deliver unparalleled value to our clients.'
Praising Grazitti for its achievement in two key categories, Rodrigo Barreto, Lead Analyst at ISG, said, 'Grazitti Interactive's recognition as a leader in the ISG Report for Managed Application Services for Midmarket highlights its strong focus on delivering value through Salesforce. Their expertise in Optimization and Quality Assurance plays a key role in this achievement.' He further mentioned, 'Their transition from a Rising Star to a Leader in Salesforce Core Cloud Implementation Services for the Midmarket quadrant reflects their continuous innovation in AI and development of solutions tailored to meet specific business needs.'
The ISG Provider Lens™ Quadrant research series evaluates service providers based on empirical data, market analysis, and insights from ISG's global advisory team. This year's report highlights Grazitti's strong portfolio, emphasizing its expertise in Salesforce core cloud implementations and managed services for the midmarket segment.
To know more about our Salesforce Professional Services, click here.
About ISG
Information Services Group (ISG) is a leading global technology research and advisory firm. With a distinguished clientele, ISG empowers organizations to navigate the complexities of modern business landscapes with confidence and agility.
About Grazitti Interactive®
Grazitti Interactive is a digital technology leader with extensive experience developing innovative solutions that unlock data insights, increase operational efficiency, and drive customer success. The company has empowered businesses of all sizes—including Fortune 500 enterprises—to implement, customize, configure, optimize, integrate, and manage solutions such as CRM, marketing automation, online communities, eCommerce, and analytics.
Download Summary
Grazitti Interactive
Grazitti Interactive
+1 650-585-6640
[email protected]
Visit us on social media:
Bluesky
YouTube
X
Other
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
33 minutes ago
- Business Upturn
Global Dermal Fillers Market is Predicted to Reach ~USD 12 Billion by 2032
By GlobeNewswire Published on July 31, 2025, 22:00 IST New York, USA, July 31, 2025 (GLOBE NEWSWIRE) — Global Dermal Fillers Market is Predicted to Reach ~USD 12 Billion by 2032 | DelveInsight The demand for dermal fillers is influenced by several major factors. First, the global increase in cosmetic procedures is largely driven by an aging population and a heightened desire to preserve a youthful look, coupled with growing aesthetic awareness. Additionally, there is a notable trend toward minimally invasive cosmetic treatments because they offer greater convenience, quicker recovery, and lower costs compared to traditional surgical options. DelveInsight's Dermal Fillers Market Insights report provides the current and forecast market analysis, individual leading dermal fillers companies' market shares, challenges, dermal fillers market drivers, barriers, trends, and key market dermal fillers companies in the market. Key Takeaways from the Dermal Fillers Market Report As per DelveInsight estimates, North America is anticipated to dominate the global dermal fillers market during the forecast period. In the material segment of the dermal fillers market, the hyaluronic acid (HA) category accounted for the largest market share in 2024. Notable dermal fillers companies such as AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and several others are currently operating in the Dermal Fillers market. and several others are currently operating in the Dermal Fillers market. In February 2025, Crown Laboratories, Inc., a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity™ and its range of RHA® 2, RHA® 3, and RHA® 4-based dermal fillers. a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity™ and its range of RHA® 2, RHA® 3, and RHA® 4-based dermal fillers. In October 2024, Allergan Aesthetics, an AbbVie company, announced the national availability of JUVÉDERM® VOLUMA® XC for the treatment of temple hollowing. This hyaluronic acid (HA) filler is approved for addressing moderate to severe temple hollowing in adults over 21. As the leading HA dermal filler brand preferred by both patients and providers, the JUVÉDERM® Collection of Fillers now offers the broadest range of treatment indications to help patients achieve their aesthetic goals. To read more about the latest highlights related to the dermal fillers market, get a snapshot of the key highlights entailed in the Global Dermal Fillers Market Report Dermal Fillers Overview Dermal fillers are injectable substances used to restore volume, smooth out wrinkles, and enhance facial contours. Composed primarily of hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, or polymethylmethacrylate beads, these fillers work by replenishing lost volume in the skin and stimulating collagen production. They are commonly used to treat areas such as the cheeks, lips, nasolabial folds, and under-eye hollows, providing a non-surgical alternative for facial rejuvenation. The effects of dermal fillers are temporary, lasting anywhere from six months to two years, depending on the type of filler and individual patient factors. The procedure is minimally invasive, typically performed in a clinical setting with little to no downtime. Local anesthesia or numbing agents may be applied to minimize discomfort during injection. While generally safe when administered by trained professionals, dermal fillers can have side effects, including swelling, bruising, redness, and in rare cases, complications like vascular occlusion or infection. Due to these risks, proper patient assessment and adherence to safety protocols are essential. Increasingly popular for their convenience and effectiveness, dermal fillers remain a leading option in cosmetic dermatology for individuals seeking subtle yet noticeable aesthetic improvements. Dermal Fillers Market Insights North America is expected to dominate the dermal fillers market in the coming years, supported by several critical factors. This leadership is largely driven by the growing number of cosmetic procedures, which are influenced by an aging population and a strong desire to maintain youthful looks. Additionally, the preference for minimally invasive aesthetic treatments, combined with a robust healthcare infrastructure, has accelerated market expansion. Rising awareness and widespread acceptance of cosmetic enhancements further reinforce this trend. Moreover, frequent product approvals and new launches from leading players continue to strengthen North America's market position. These dynamics are anticipated to maintain the region's dominance throughout the forecast period of 2025–2032. A key growth driver in the region is the increasing volume of aesthetic procedures, reflecting the rising demand for non-surgical treatments that deliver quick results with minimal recovery time. This surge is fueled by greater awareness, societal acceptance of cosmetic improvements, and a growing elderly population seeking effective anti-aging solutions. In addition, major industry players are actively investing in R&D to develop advanced dermal filler products tailored for regional needs. For instance, in June 2023, Galderma received FDA approval for Restylane® Eyelight, specifically designed to treat under-eye hollows in adults over 21. It is the first and only HA filler in the U.S. featuring NASHA® Technology to restore under-eye volume and deliver natural results. Similarly, in February 2022, Allergan Aesthetics, an AbbVie company, secured FDA approval for JUVÉDERM® VOLBELLA® XC for treating infraorbital hollows in adults over 21. This product also serves as a lip augmentation solution and helps correct perioral lines, enhancing overall facial aesthetics. Together, the growing demand for cosmetic procedures and strategic product innovations are fueling the dermal fillers market in North America, solidifying its status as a leading region in the global market. To know more about why North America is leading the market growth in the dermal fillers market, get a snapshot of the Dermal Fillers Market Outlook Dermal Fillers Market Dynamics The dermal fillers market is experiencing significant growth, driven primarily by the increasing demand for minimally invasive aesthetic procedures. Rising awareness about cosmetic enhancements and the desire for youthful appearances have fueled the adoption of dermal fillers across various demographics. Factors such as the aging global population, especially in developed economies, and growing disposable incomes in emerging markets have further contributed to market expansion. These procedures are preferred for their relatively quick recovery time and non-surgical nature, which aligns with the current trend toward less invasive treatment options. Technological advancements in dermal filler products have also played a crucial role in shaping market dynamics. Innovations in filler composition, including the introduction of hyaluronic acid-based and biostimulatory fillers, have improved safety profiles, longevity, and natural results. Moreover, ongoing research and development efforts by key players to develop fillers with longer-lasting effects and fewer side effects continue to enhance product appeal. These advancements have not only expanded the scope of applications but have also increased patient satisfaction, encouraging repeat procedures and contributing to market growth. Regulatory approvals and favorable reimbursement policies in certain regions further support the expansion of the dermal fillers market. However, stringent regulations in countries with established healthcare systems can act as barriers for new entrants. Additionally, the rise of medical tourism in countries like Thailand, India, and Mexico has created new growth opportunities for service providers and manufacturers, as patients seek affordable yet high-quality aesthetic treatments. Despite these positive trends, the dermal fillers market faces challenges such as the risk of complications, including allergic reactions and improper injections leading to vascular occlusion. Additionally, the availability of counterfeit or substandard products in some markets poses safety concerns and threatens consumer confidence. Competition from alternative aesthetic procedures like botulinum toxin injections and energy-based devices also adds pressure to the market. Nevertheless, continuous innovation, increasing social acceptance, and the growing influence of social media on beauty standards are expected to sustain robust growth in the coming years. Get a sneak peek at the dermal fillers market dynamics @ Dermal Fillers Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Dermal Fillers Market CAGR ~8% Dermal Fillers Market Size by 2032 ~USD 12 Billion Key Dermal Fillers Companies AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., among others Dermal Fillers Market Assessment Dermal Fillers Market Segmentation Dermal Fillers Market Segmentation By Product Type: Biodegradable Fillers and Non-Biodegradable Fillers Dermal Fillers Market Segmentation By Route of Material: Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others Dermal Fillers Market Segmentation By Route of Gender: Male and Female Dermal Fillers Market Segmentation By End-User: Hospitals, Dermatology Clinics, and Others Dermal Fillers Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the dermal fillers market are set to emerge as the trendsetter explore @ Dermal Fillers Analysis Table of Contents 1 Dermal Fillers Market Report Introduction 2 Dermal Fillers Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Dermal Fillers Market Key Factors Analysis 6 Dermal Fillers Market Porter's Five Forces Analysis 7 Dermal Fillers Market Layout 8 Dermal Fillers Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the dermal fillers market by 2032? Click to get a snapshot of the Dermal Fillers Market Analysis Related Reports Aesthetic Implants Market Aesthetic Implants Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key aesthetic implants companies, including POLYTECH Health & Aesthetics GmbH, Sientra, Inc, Surgiform Innovative Surgical Products, GC Aesthetics, Dentsply Sirona, Institut Straumann AG, AVINENT, AbbVie, Establishment Labs S.A., Mentor (Johnson & Johnson Medical Ltd), 3M, Zimmer Biomet, Alpha Aesthetics, Symatese, Integra LifeSciences, Sebbin, IDEAL IMPLANT INCORPORATED, Lattice Medical, CEREPLAS, Guangzhou Wanhe Plastic Material Co Ltd, among others. Medical Aesthetic Devices Market Medical Aesthetic Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key medical aesthetic devices companies, including Johnson & Johnson, HansBioMed., AbbVie Inc., Sebbin, Sientra, Inc., POLYTECH Health & Aesthetics GmbH, Suneva Medical, Hanson Medical Inc., SurgiSil, Surgiform Technologies LLC, Alma Lasers, Candela Medical., Lumenis., Cutera., Sciton Inc, Merz Pharma GmbH & Bausch Health Companies Inc., Venus Concept., TRIA BEAUTY, Cynosure Inc., GALDERMA, among others. Aesthetic Thread Market Aesthetic Thread Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key aesthetic thread companies, including Aptos International Ltd, Intraline, Healux Corporation, Croma Pharma GambH, Les Encres Cosmetic Threads, W & O Medical Esthetics Gmbh, Hyundae Meditechh Co. Ltd., N-Finders Co., Ltd., Nova Threads, Savia medical, Metro Korea Co., Ltd., RIVER AESTHETICS, Spring Thread, RELIFE S.r.l., Sinclair, MINT™, PDO MAX, Promoitalia, EWELL Medical., illari Threads, among others. Aesthetic Lasers Market Aesthetic Lasers Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key aesthetic lasers companies, including Boston Scientific Corporation, Candela Medical, Lynton Lasers, Lutronic, Fotona, Alma Lasers, Sciton, Astanza Laser, Konmison, AMI INC., Lumibird Medical (Ellex), Cutera, biolitec® Holding GmbH & Co KG, Cartessa Aesthetics, Beagle E-Comm Private Limited, WON TECH Co., Ltd., Attikouris Enterprises Ltd., Aftab Forouzan Aria Company, SL LASERS, Reveal Lasers LLC, among others. Energy-Based Aesthetic Devices Market Energy-Based Aesthetic Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key energy-based aesthetic devices companies, including Alma Lasers, Candela Medical, Lumenis, Cutera, Hologic Inc., Sciton Inc., Merz Pharma GmbH & Bausch Health Companies Inc., Venus Concept, TRIA BEAUTY, Cynosure Inc., SharpLight Technologies Inc., Lutronic, Fotona, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Wire
an hour ago
- Business Wire
Cotiviti's Quality Measurement and Reporting Solution Achieves 25th Consecutive Year of HEDIS® Measure Certification
SALT LAKE CITY--(BUSINESS WIRE)--Quality Engine, the administrative measure logic and sample processing component of Cotiviti's Quality Intelligence solution, has earned HEDIS® Certified Measures™ status from the National Committee for Quality Assurance (NCQA) for Measurement Year (MY) 2025. HEDIS Measure Certification validates that Cotiviti's measures have been put through the thorough testing required to effectively support health plans with the HEDIS MY 2025 season. This milestone marks an industry-leading 25 consecutive years of certification, demonstrating Cotiviti's ability to adapt and serve as a long-term partner to health plans as the HEDIS program continually evolves. This milestone marks an industry-leading 25 consecutive years of certification, demonstrating Cotiviti's ability to adapt and serve as a long-term partner to health plans as the HEDIS program continually evolves. Share 'The ongoing transition to fully digital quality measurement requires health plans to have a quality improvement solution that not only meets the highest standards for accuracy, but continually evolves to meet and exceed new requirements,' said Emad Rizk, M.D., chairman, president, and CEO of Cotiviti. 'This achievement reflects Cotiviti's unwavering commitment to supporting our health plan clients. It speaks to the deep expertise we've built through decades of working with billions of data points, navigating complex measurement requirements, and helping our clients meet the changing demands of quality reporting.' Cotiviti's Quality Intelligence processes more than 147 million member lives reported to NCQA and serves as a comprehensive measurement and reporting solution that streamlines compliance while supporting HEDIS, state-specific, and other quality measure submissions. Newly launched in 2025, Cotiviti's Engagement Hub integrates with Quality Intelligence to drive coordination and efficiency through a centralized member engagement and reporting platform, enabling plans to close care gaps to ultimately improve quality scores. Further integrations within Cotiviti's quality improvement ecosystem support year-round quality improvement and enable better member health. When integrated with Cotiviti's Star Intelligence, Quality Intelligence provides a centralized platform for managing both HEDIS and Star Ratings, helping clients ensure consistency across programs and maintain compatibility with historical data to support accurate trending and projections. Cotiviti's scalable medical record retrieval and abstraction services also connect directly with the solution to enable end-to-end support for health plans throughout the HEDIS season. 'Payers need a trusted partner in quality improvement with a longstanding track record of success to help them navigate the digital quality transition and deliver high-performing, reliable solutions that have been continuously refined and supported over decades,' said Chad Kinkead, executive vice president of risk adjustment, quality, and engagement for Cotiviti. 'Cotiviti's Quality Intelligence supports all members and lines of business with end-to-end capabilities for accurate processing, reporting, audits, and submissions, backed by a team of experts who are committed to supporting health plans during and after the transition to digital reporting. Our clients can anticipate further innovation as we integrate Cotiviti's industry-leading quality improvement, DxCG risk assessment, engagement, and risk adjustment solutions with Edifecs' leading NLP-enabled coding platform, interoperability capabilities, and AI-enabled value based-payment solutions." About Cotiviti Cotiviti enables healthcare organizations to deliver better care at lower cost through advanced technology and data analytics that improve the quality and sustainability of healthcare in the United States. Cotiviti's solutions increase transparency and collaboration between payers and providers while empowering them to reduce medical and administrative costs, enable better health, improve claims payment efficiency, streamline operations, drive interoperability, and advance value-based care. Its customers serve the majority of U.S. healthcare consumers, providing coverage and care for over 300 million members and patients. Additionally, Cotiviti offers data management and recovery audit services to the retail sector to improve business outcomes. For more information, visit About NCQA NCQA is a private, non-profit organization dedicated to improving healthcare quality. NCQA accredits and certifies a wide range of healthcare organizations. It also recognizes clinicians and practices in key areas of performance. NCQA's website contains information to help consumers, employers and others make more informed healthcare choices.
Business Wire
3 hours ago
- Business Wire
Closure Systems International Launches Defender-Lok™ CRC Product Line
INDIANAPOLIS--(BUSINESS WIRE)--Closure Systems International (CSI), a global leader in closure design and manufacturing, announces the launch of its new child-resistant closure (CRC) platform: Defender-Lok™. Engineered for OTC and nutraceutical applications, Defender-Lok delivers certified safety, operational efficiency, and sustainability in a drop-in, high-performance solution. Built for Line Efficiency and Compliance Defender-Lok is designed to integrate seamlessly into existing capping and filling lines—minimizing downtime, feeder jams, and sealing failures. The result: optimized production, simplified validation, and consistent throughput. The closures are certified child-resistant and senior-friendly, offering peace of mind to both manufacturers and consumers. 'In the OTC and nutraceutical market, child-resistant closures demonstrate a brand's commitment to consumer safety and regulatory compliance. A well-engineered design meets the expectations of today's health-conscious shoppers, ensures compliance, and integrates seamlessly with high-speed filling and capping lines,' said Chuck Newswanger, Director, Global Commercial Innovation and Technical Development–Pharmaceutical Packaging at CSI. Key features of Defender-Lok include: Certified CRC Design – Child-resistant and senior-friendly, meeting regulatory standards Drop-In Compatibility – Ready for existing OTC/nutraceutical lines Sustainable Engineering – Up to 33% lighter than conventional CRCs; supports PolyCycle™ PCR resin integration Tamper-Evident & Liner Agnostic – Compatible with all liners including foam, tri-foil, induction seal, pressure-sensitive, and custom High-Speed Performance – Maintains line speed, reduces errors, and improves yield Flexible Formats – Available in 33mm, 38mm, 45mm, and 53mm sizes; suitable for dry or liquid products Sustainability by Design With growing Extended Producer Responsibility (EPR) requirements and state-level mandates like California's SB-54, sustainability is no longer optional. Defender-Lok is designed for material minimization—reducing resin use, shipping weight, and overall environmental impact. Select SKUs already exceed 2027 SB-54 targets, and all closures in the line can be produced using CSI's PolyCycle™ PCR resin, which is made from post-consumer content and fully recyclable. Backed by Global Scale and Technical Expertise CSI brings more than 90 years of experience and operates nine manufacturing sites across the U.S., Mexico, Costa Rica, China, and Japan. All CRC products, including Defender-Lok, are manufactured in FSSC-22000 certified facilities with in-house tooling and R&D support. CSI also offers customers full application assistance, including on-site technical service, validation audits, and commercialization support. Defend Product Integrity – Lok In Performance To learn more about the Defender-Lok CRC line or to speak with CSI's technical packaging team, visit: About Closure Systems International Closure Systems International (CSI) is a global leader in closure design, manufacturing, and innovation. CSI supplies billions of closures annually across the beverage, food, household, and healthcare sectors. Learn more at
